Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.
作者信息
Baum Michel
出版信息
J Pediatr Hematol Oncol. 2010 Oct;32(7):525-6. doi: 10.1097/MPH.0b013e3181ec0c4d.
Abstract
摘要
相似文献
1
Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.
J Pediatr Hematol Oncol. 2010 Oct;32(7):525-6. doi: 10.1097/MPH.0b013e3181ec0c4d.
2
Fanconi syndrome due to deferasirox.
Am J Kidney Dis. 2009 Nov;54(5):931-4. doi: 10.1053/j.ajkd.2009.03.013. Epub 2009 Jun 3.
3
Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
J Pediatr Hematol Oncol. 2010 Oct;32(7):564-7. doi: 10.1097/MPH.0b013e3181ec0c38.
4
Acute renal failure and Fanconi syndrome due to deferasirox.
Nephrol Dial Transplant. 2010 Jul;25(7):2376-8. doi: 10.1093/ndt/gfq224. Epub 2010 Apr 20.
5
Reversible Fanconi syndrome in a pediatric patient on deferasirox.
Pediatr Blood Cancer. 2011 Apr;56(4):674-6. doi: 10.1002/pbc.22711. Epub 2010 Dec 6.
6
A case report of deferasirox-induced kidney injury and Fanconi syndrome.
WMJ. 2013 Aug;112(4):177-80.
7
Deferasirox and renal dysfunction in children.
Pediatr Nephrol. 2012 Nov;27(11):2159. doi: 10.1007/s00467-012-2226-5. Epub 2012 Aug 15.
8
Charge states of deferasirox-ferric iron complexes.
Am J Kidney Dis. 2010 Mar;55(3):614-5. doi: 10.1053/j.ajkd.2009.10.065.
9
Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.
Nephrology (Carlton). 2015 Dec;20(12):931-5. doi: 10.1111/nep.12523.
10
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Br J Haematol. 2014 Nov;167(3):434-6. doi: 10.1111/bjh.13002. Epub 2014 Jul 2.
引用本文的文献
1
Unusual Association of Partial Fanconi Syndrome and Tumor-Induced Osteomalacia Revealed by Multiple Vertebral Fractures.
Calcif Tissue Int. 2025 Jan 31;116(1):36. doi: 10.1007/s00223-025-01344-2.
2
Deferasirox - a rarer cause of Fanconi syndrome.
J Community Hosp Intern Med Perspect. 2019 Sep 5;9(4):358-359. doi: 10.1080/20009666.2019.1650592. eCollection 2019.
3
What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.
Ther Clin Risk Manag. 2018 Sep 7;14:1649-1655. doi: 10.2147/TCRM.S170761. eCollection 2018.
4
Deferasirox nephrotoxicity-the knowns and unknowns.
Nat Rev Nephrol. 2014 Oct;10(10):574-86. doi: 10.1038/nrneph.2014.121. Epub 2014 Jul 22.
5
Iron metabolism in the pathogenesis of iron-induced kidney injury.
Nat Rev Nephrol. 2013 Jul;9(7):385-98. doi: 10.1038/nrneph.2013.98. Epub 2013 May 14.
6
Anticonvulsant-induced rickets and nephrocalcinosis.
BMJ Case Rep. 2012 Feb 25;2012:bcr1220115359. doi: 10.1136/bcr.12.2011.5359.
7
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Pediatr Nephrol. 2012 Nov;27(11):2115-2122. doi: 10.1007/s00467-012-2170-4. Epub 2012 Apr 24.
8
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.
Blood. 2012 Apr 5;119(14):3263-8. doi: 10.1182/blood-2011-10-386268. Epub 2012 Jan 17.
本文引用的文献
1
Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
J Pediatr Hematol Oncol. 2010 Oct;32(7):564-7. doi: 10.1097/MPH.0b013e3181ec0c38.
2
Acute renal failure and Fanconi syndrome due to deferasirox.
Nephrol Dial Transplant. 2010 Jul;25(7):2376-8. doi: 10.1093/ndt/gfq224. Epub 2010 Apr 20.
3
Charge states of deferasirox-ferric iron complexes.
Am J Kidney Dis. 2010 Mar;55(3):614-5. doi: 10.1053/j.ajkd.2009.10.065.
4
Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
Am J Hematol. 2010 Feb;85(2):132-4. doi: 10.1002/ajh.21588.
5
Fanconi syndrome due to deferasirox.
Am J Kidney Dis. 2009 Nov;54(5):931-4. doi: 10.1053/j.ajkd.2009.03.013. Epub 2009 Jun 3.
6
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Blood. 2006 May 1;107(9):3455-62. doi: 10.1182/blood-2005-08-3430. Epub 2005 Dec 13.
7
Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation.
Biochim Biophys Acta. 1999 Nov 10;1413(3):99-107. doi: 10.1016/s0005-2728(99)00088-2.
8
Role of adenosine triphosphate (ATP) and NaK ATPase in the inhibition of proximal tubule transport with intracellular cystine loading.
J Clin Invest. 1991 Mar;87(3):955-61. doi: 10.1172/JCI115103.
Zotero 插件